Niki Arrowsmith04.09.13
David B. Kaysen has resigned his post as president, CEO and board member for Uroplasty Inc., a Minneapolis, Minn.-based maker of medical devices for the treatment of voiding dysfunctions. Independent director Robert C. Kill has been named interim CEO while the board of directors conducts a search for a permanent replacement.
“Dave Kaysen has served as our president and CEO since May 2006 and has guided the company through the introduction of its industry leading UrgentPC product, including successful completion of clinical trials that resulted in a category 1 CPT code as well as Medicare reimbursement for that product in most jurisdictions,” said Chairman of the Board James Stauner. “Dave assumed the CEO role when Uroplasty had virtually all of its operations in Europe and generated only $6.4 million in revenue. He departs with the company generating over $22 million in annual sales, largely fueled by growth in Urgent PC sales. We truly appreciate all of Dave’s contributions and wish him the best in his future endeavors.”
Rob Kill, who has been a director with Uroplasty since 2010, is currently an operating partner with Altamont Capital Partners, a private equity firm. Prior to joining Altamont, Kill was president and CEO of Virtual Radiologic Corporation, a provider of technology-enabled outsourced radiology solutions. Before Virtual Radiologic, he was President of Misys Physician Systems, a developer of electronic medical record and practice management software. Kill was with Baxter Healthcare for the first ten years of his career, where he held senior leadership roles in operations, marketing and sales.
UrgentPC, one of Urplasty’s flagship products, is a prescription medical device used to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
“Dave Kaysen has served as our president and CEO since May 2006 and has guided the company through the introduction of its industry leading UrgentPC product, including successful completion of clinical trials that resulted in a category 1 CPT code as well as Medicare reimbursement for that product in most jurisdictions,” said Chairman of the Board James Stauner. “Dave assumed the CEO role when Uroplasty had virtually all of its operations in Europe and generated only $6.4 million in revenue. He departs with the company generating over $22 million in annual sales, largely fueled by growth in Urgent PC sales. We truly appreciate all of Dave’s contributions and wish him the best in his future endeavors.”
Rob Kill, who has been a director with Uroplasty since 2010, is currently an operating partner with Altamont Capital Partners, a private equity firm. Prior to joining Altamont, Kill was president and CEO of Virtual Radiologic Corporation, a provider of technology-enabled outsourced radiology solutions. Before Virtual Radiologic, he was President of Misys Physician Systems, a developer of electronic medical record and practice management software. Kill was with Baxter Healthcare for the first ten years of his career, where he held senior leadership roles in operations, marketing and sales.
UrgentPC, one of Urplasty’s flagship products, is a prescription medical device used to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.